Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FX Other monoclonal antibodies and antibody drug conjugates
L01FX17 Sacituzumab govitecan
D10985 Sacituzumab govitecan (USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Sacituzumab Govitecan
D10985 Sacituzumab govitecan (USAN/INN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
Other
TACSTD2 (TROP2)
D10985 Sacituzumab govitecan (USAN/INN) <US>
Enzymes
Isomerases (EC5)
DNA topoisomerase
TOP1
D10985 Sacituzumab govitecan (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10985
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10985
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10985
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10985
Polymorphisms and mutations affecting drug response
D10985
